RADX stock sentiment todayRadiopharm Theranostics Ltd
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
RADX
Radiopharm Theranostics LtdA high-risk, high-reward radiopharmaceutical play with promising technology but thin liquidity and significant cash burn typical of early-stage biotech.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for RADX. Not financial advice.
Price · last 12 months
Gossip
Market chatter focuses on the company's recent Nasdaq listing (June 2024) and its status as a 'pure-play' in the trending radiopharmaceutical space. While retail interest is piqued by the sector's M&A heat (e.g., AstraZeneca/Fusion), RADX is currently struggling for volume and visibility compared to its Australian (ASX: RAD) counterpart.
- ·Speculation on M&A potential in the radioligand therapy sector
- ·Anticipation of Phase 1/2 clinical data readouts
- ·Recent Nasdaq uplisting attracting institutional eyes
Financial
Financials reflect a pre-revenue clinical-stage biotech. The company maintains a high burn rate to fund its diverse pipeline. While they recently secured institutional funding (led by Lantheus), the runway is limited, necessitating further dilution or partnerships in the next 12-18 months.
- ·Negative EPS consistent with R&D phase
- ·Stronger cash position following June 2024 institutional placement
- ·No current revenue from product sales
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Clinical trial failure or delays across the lead candidate (LRRC15)
- ·Significant dilution risk from future capital raises
- ·Low trading liquidity on the Nasdaq compared to industry peers
Peer temperature
How direct competitors stack up against RADX right now.
- HOTRLAYRelay Therapeutics
HOTTER — significantly larger cash runway and more robust institutional backing for its computational drug discovery platform.
See full analysis → - HOTLTHMLantheus Holdings
HOTTER — profitable with a dominant market share in radiopharmaceutical diagnostics, providing a safer floor than RADX.
See full analysis → - NEUTRALACTGEnliven Therapeutics
NEUTRAL — similar clinical-stage risk profile but possesses a more concentrated pipeline in validated kinase inhibitors.
See full analysis →
- RADX-33.3%
- RLAY+1.7%
- LTHM—
- ACTG+0.5%
Analyst price target
Consensus average of 1 analyst · median 16.00
Source: StockAnalysis.com · updated 2026-06-04
AI-generated analysis for informational purposes only. Not financial advice.